Eligibility for extended antithrombotic therapy for secondary prevention of acute coronary syndrome

Eligibility for extended antithrombotic therapy for secondary prevention of acute coronary syndrome

Show other versions (1)

Introduction and Objectives: Recent randomized controlled trials have evaluated the benefit of extended antithrombotic therapy in secondary prevention of acute coronary syndrome (ACS). However, the numerous and strict enrollment criteria may limit the validity and reproducibility of the published re...

Full description

Bibliographic Details
Main Authors: Daniel Faria, Miguel Santos, Sérgio Bravo Baptista, João Ferreira, Paulo Leal, Pedro Farto e Abreu, Carlos Morais
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:Revista Portuguesa de Cardiologia (English Edition)
Subjects:
Ticagrelor
Rivaroxabano
Síndrome coronária aguda
Terapêutica antitrombótica
Online Access:http://www.sciencedirect.com/science/article/pii/S2174204920303160

Internet

http://www.sciencedirect.com/science/article/pii/S2174204920303160

Similar Items